Sign up for a new account.
And get access to
The latest T1D content
Research that matters
Our daily questions
Sign up by entering your info below.
Reset Your Password
We will email you instructions to reset your
CGM devices have been shown to improve glycemic control in patients with T1D. Despite existing clinical evidence and improved performance of CGM devices, only a small proportion of patients are using CGM.
The T1D Exchange QI Collaborative (T1DX-QI) is a large cohort with twelve national clinics engaged in data sharing and quality improvement to improve outcomes. This analysis used the T1DX-QI database to examine patient attributes associated with CGM device use. Patients with one or more completed clinic encounters during the years 2017–2019 were included (N = 16,414) and classified as CGM users if they indicated information on a device start date, model or company within the past one year of their most recent diabetes clinic visit. We examined the frequency of CGM device use and distribution of socio-demographic factors, as well as clinical outcomes, among CGM users versus non-users.
In this cohort, 5486 (33.4%) of T1D patients were CGM users, with patients aged ≤26 years being more likely to use CGM (48%). Among CGM users, about 60% used a real-time device, 2% used an intermittent scanning device, whereas for 38% device type was unknown. CGM use was more likely among Non-Hispanic Whites (75%) and patients on private health insurance (77%) relative to Non-Hispanic Black patients (2%) and those on public health insurance (20%) [p < 0.001]. HbA1c levels among CGM users were lower relative to non-users after adjusting for age, race/ethnicity and insurance status (8.0% ± 1.7% vs. 8.8% ±1.9%) [p < 0.001].
This study highlights real world evidence of patient factors and clinical outcomes among CGM users in the T1DX-QI Collaborative. This distribution of patient attributes comes from one of the largest T1D cohort’s available to-date and sheds light on sociodemographic variability in CGM uptake with implications for targeted interventions to promote device used in this subset of the T1D population.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Join our mailing list for more about T1D
- Dr. Osagie Ebekozien Awarded ISPAD’s Prize for Innovation in Pediatric Diabetes Careby Sarah TackettOctober 13, 2021
- T1D Exchange Research Highlights from ISPAD 2021by Sarah TackettOctober 13, 2021
- Status Update: Connected Insulin Delivery Devicesby Hope WarshawOctober 7, 2021
- Top Questions of the Day – September 2021by Sarah TackettSeptember 30, 2021
- Connect1d Canada partners with the T1D Exchangeby Deborah TaylorSeptember 20, 2021